Liver toxicity in the era of immune checkpoint inhibitors: A practical approach
- 1 December 2018
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 132, 125-129
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Pathologic Changes in Ipilimumab-Related Hepatitis in Patients with Metastatic MelanomaDigestive Diseases and Sciences, 2012
- The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injuryHepatology, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Inhibitory B7-family molecules in the tumour microenvironmentNature Reviews Immunology, 2008
- PD-1 and Its Ligands in Tolerance and ImmunityAnnual Review of Immunology, 2008
- PD-1 and PD-1 ligands: from discovery to clinical applicationInternational Immunology, 2007
- PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T CellsCancer Research, 2004
- Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte ActivationJournal of Experimental Medicine, 2000
- The Role of CTLA‐4 in the Regulation and Initiation of T‐Cell ResponsesImmunological Reviews, 1996
- Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivoInternational Immunology, 1996